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ABSTRACT
Limbal stem cell deﬁciency (LSCD) is a disease resulting from the loss or dysfunction of epithelial
stem cells, which seriously impairs sight. Autologous limbal stem cell transplantation is effective
in unilateral or partial bilateral disease but not applicable in total bilateral disease. An allogeneic
source of transplantable cells for use in total bilateral disease can be obtained from culture of
donated cadaveric corneal tissue. We performed a controlled multicenter study to examine the
feasibility, safety, and efﬁcacy of allogeneic corneal epithelial stem cells in the treatment of bilat-
eral LSCD. Patients were randomized to receive corneal epithelial stem cells cultured on amniotic
membrane (AM): investigational medicinal product (IMP) or control AM only. Patients received
systemic immunosuppression. Primary endpoints were safety and visual acuity, secondary end-
point was change in composite ocular surface score (OSS). Sixteen patients were treated and
13 patients completed all assessments. Safety was demonstrated and 9/13 patients had improved
visual acuity scores at the end of the trial, with no signiﬁcant differences between IMP and control
groups. Patients in the IMP arm demonstrated signiﬁcant, sustained improvement in OSS,
whereas those in the control arm did not. Serum cytokine levels were measured during and after
the period of immune suppression and we identiﬁed strongly elevated levels of CXCL8 in the
serum of patients with aniridia, which persisted throughout the trial. This ﬁrst randomized control
trial of allogeneic corneal epithelial stem cells in severe bilateral LSCD demonstrates the feasibility
and safety of this approach. STEM CELLS TRANSLATIONAL MEDICINE 2019;00:1–9
SIGNIFICANCE STATEMENT
This ﬁrst randomized control trial of allogeneic corneal epithelial stem cells on amniotic membrane
in severe bilateral limbal stem cell deﬁciency demonstrates the feasibility and safety of this
approach. The fully controlled trial, including a control product and use of immune suppression in
both arms, allowed deﬁnitive measurement of the effects of the stem cell-containing-product.
There was evidence of sustained improvement in ocular surface score in the stem cell arm and
some evidence of improved visual acuity in both arms. Studies examining speciﬁc etiologies of LSCD
will further deﬁne the role of this technique in treating severe bilateral disease.
INTRODUCTION
The surface of the cornea is maintained by cor-
neal epithelial stem cells located in the transition
zone between the cornea and conjunctiva—the
limbus [1, 2]. Limbal stem cell deﬁciency (LSCD)
is an irreversible disease resulting from the loss
or dysfunction of these epithelial stem cells. The
corneal epithelium becomes deﬁcient and is
replaced by the surrounding conjunctival epithe-
lium, resulting in a thickened, irregular, unstable
epithelium, often with secondary neovasculariza-
tion, and inﬂammation [3]. LSCD causes severe
ocular surface disease (OSD) characterized by
reduced vision or blindness, chronic ocular irrita-
tion, and glare [3]. LSCD can be differentiated
into two etiological subcategories [4]. Category
1—aplasia or destruction of limbal stem cells
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from chemical and thermal burns. Category 2—loss of limbal stem
cell function due to insufﬁcient stromal support and includes aniri-
dia, multiple endocrine deﬁciency syndrome.
Standard corneal transplantation is not an effective treat-
ment for LSCD. Several case series have provided evidence
that grafting viable whole limbal tissue, either from the fellow
healthy eye [5] or donor eye [6], may replenish the host cor-
neal epithelium. Large autologous limbal grafts, however, may
compromise the healthy donor eye, whereas large allogeneic
donor grafts often fail despite immune suppression. Smaller
limbal tissue quantities can potentially reduce these limitations
and advances in tissue engineering techniques can provide
ex vivo expanded autologous or allogeneic corneal epithelium
[7–9] with a success rate of approximately 76% in LSCD [9].
Many studies have been published but these form discrete
data sets [10–20]. A recent review of the ﬁeld indicates 9 pub-
lished uses of allogeneic donated material for treating LSCD in
approximately 80 patients [20]. However, this is not a coherent
body of data, with cadaveric and living related donors; differ-
ing culture methods; variable follow-up times, some of less
than 1 year; and great variability in success criteria. Critically
none of the allogeneic studies have contained a control arm
against which results can be compared. Frequently the studies
are single-center due to logistics of transporting clinical grade
ex vivo expanded corneal epithelial stem cells. Critically, it is
not clear whether the clinical outcome of LSC replacement is
independent of biological effect(s) of concomitant surgical
pannus excision, amniotic membrane (AM) resurfacing, and
immunosuppression. Therefore, our study aimed to address
the following. (a) Manufacture of allogeneic ex vivo expanded
corneal epithelial stem cells on AM at Good Manufacturing
Practice (GMP) standard. (b) A randomized controlled study to
investigate safety and efﬁcacy of this investigational medicinal
product (IMP). The clinical trial was designed as a randomized,
controlled, and partially blinded phase I/II trial and hypothe-
sized that the use of AM, topical autologous serum eye drops
and systemic immunosuppression, may have therapeutic bene-
ﬁt. By this highly controlled design it was anticipated that true
effects of stem cells in the IMP would be quantiﬁed.
MATERIALS AND METHODS
Trial Ethics and Review Board Approval
The protocol was approved by SNBTS, and was reviewed and
approved by the Lothian Research Ethics Committee June
22, 2011 REC 14/ES/1008. The study was conducted in accor-
dance with the requirements of the International Conference
on Harmonization for Good Clinical Practice (GCP) Tripartite
Guideline. The study was performed under a Medicines and
Healthcare Products Regulatory Agency’s Clinical Trials Autho-
rization, Eudract Number 2010-024409-01.
The trial results are now in the public domain: https://www.
clinicaltrialsregister.eu/ctr-search/trial/2010-024409-11/results
GMP Manufacturing of Corneal Epithelial Stem Cell
Product
All study materials were prepared in strict compliance with EU
GMP as deﬁned in Directive 2003/94/EC under the SNBTS Manu-
facturer’s Authorization for Investigational Medicinal Products
(MIA [IMP], 3473).
Eye Tissue. Eyes were procured from deceased donors under
appropriate organ and tissue donation consent within 24 hours
of death and sent to either the Manchester or Bristol Eye Banks.
All donors were virology tested at the NHS Blood and Transplant
(NHSBT) National Transfusion Microbiology Reference Labora-
tory according to the requirements of the Human Tissue (Quality
and Safety for Human Application) Regulations 2007.
Manufacture of the IMP and Control Product. Culture medium
was High Glucose Dulbecco’s modiﬁed Eagle’s medium: Hams F12 at
a 3:1 ratio (PAA, Pasching, Austria or Life Technologies, Paisley, UK),
supplemented to a ﬁnal concentration of 10% human AB serum
(SNBTS), 0.4 μg/ml hydrocortisone (Efcortesol, Sovereign Medical,
Basildon, UK), 0.13 IU/ml insulin (Humulin S: Lilly, Basingstoke, UK),
1.4 ng/ml triiodo-L-thyronine (Goldshield Pharmaceuticals, Croydon,
UK)—all clinical grade, plus 33 μg/ml adenine (Sigma, Gillingham,
UK) and 10 ng/ml epidermal growth factor (Sigma).
The clinical grade AM was supplied frozen by NHSBT, thawed
and washed three times with saline and positioned onto an auto-
claved glass coverslip, following the method of Kolli et al. [11]. On
receipt, the orientation of the cornea was not marked and as such
it was not possible to identify superior and inferior regions of the
limbus. Explants for culture were taken from adjacent regions
on the limbus. Corneal tissues were dissected into explants, so
that the dimensions of each explant was 1 mm by 2–3 mm
(with the longer dimension across the corneal/sclera junction)
such that clear corneal and white sclera could be observed macro-
scopically on each explant and to ensure there was an intact limbal
zone centrally. A sample of corneal tissue was also collected for
DNA ﬁngerprinting. Up to 5 pieces of dissected limbal tissue, epi-
thelial side up, were evenly distributed over the prepared AM and
1.5 ml of prewarmed culture medium was added to the composite
graft. The culture was then incubated at 37C, 5% CO2 with media
changes every 2–3 days for 12–19 days until the culture showed
outgrowth from the limbal explants measuring ≥200 mm2. Multi-
ple cultures were generated from each donated tissue.
Control and Distribution of IMP and Control Product. During
process validation, test cultures were assessed for shelf life as
follows: at the end of the culture period when outgrowth had
reached ≥200 mm2, the culture was fed with fresh media
(2.5 ml), then sealed with sanitized paraﬁlm and the shelf-life
assessed by incubating the cultures at 18C–24C in a Medibox
Lite Portable transport container (Abacus Instruments Ltd.) for
8 or 24 hours. Two of the cultures used for the 24 hours shelf-
life assessment also included a period with transport simula-
tion (the culture was placed on a see-saw rocker (Stuart)
within a controlled temperature incubator (RS Biotech 170R)
for up to 9–10 hours). At the end of the shelf-life period under
assessment, outgrowth regions of each culture (3mm × 4mm)
were dissected and ﬁxed in 4% formaldehyde in phosphate-
buffered saline (PBS) then assessed for morphological integrity
by H&E stain, expression of the epithelial stem cell marker p63
(clone 4A4 recognizes all isoforms of p63—TN and deltaN) and
the corneal epithelial marker cytokeratin 3 (CK3) by immuno-
histochemical analysis as detailed below.
During the clinical trial, replicate (normally duplicate) com-
posite cultures were prepared. On the planned release day,
the culture to be transplanted was fed with 2.5 ml fresh
medium and dishes sealed for transport using sanitized paraf-
ilm. Unused replicate culture(s) were retained for QC analysis.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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The released product was transferred to the operating theater
at 18C–24C in a Medibox Lite Portable transport container
(Abacus Instruments Ltd.) and retained until use. The culture
media was removed then the composite graft and was rinsed
with sterile balanced salt solution (Alcon) before transplan-
tation. Surgery was performed in Edinburgh, Glasgow, or
Liverpool at the institutions listed in the author addresses. Con-
trol product for transplantation was prepared as above, without
addition of limbal tissue and cultured for 10–14 days.
Quality Control of Product—Immunohistochemistry. The immu-
nohistochemistry testing was performed as part of the routine
service provided by the Department of Pathology, University
of Edinburgh. Brieﬂy, QC samples were placed in 4% formalde-
hyde in PBS. The samples were stained for the epithelial stem
cell marker p63 (clone 4A4 recognizes all isoforms of p63—TN
and deltaN—Abcam cat no. P3737) and the corneal epithelial
marker cytokeratin 3 (CK3) following the methods of Kolli
et al. [11] using an HRP polymer-based detection on Leica
Bond Max staining robots. Visualization was with DAB and
Hematoxylin counterstain. Staining levels were reported by an
independent pathologist.
Patient Cohort
Patient characteristics are detailed in Table 1.
Autologous Serum Eye Drops
Trial patients donated a unit of whole blood under SNBTS
Blood Establishment Authorization before commencement of
the study. Serum was collected by SNBTS Component Manufactur-
ing and preservative-free serum eye drops were manufactured
under NHSBT MHRA Specials license. Patients administered drops
to the affected eye daily as required throughout the trial and
compliance with the regimen was checked at each clinical visit.
Clinical Study Design
The study was a single-blind, randomized control clinical study
designed to treat 20 patients in 2 groups. Randomization method
is described in supplementary information. Patients were ran-
domized to receive either allogeneic corneal epithelial stem cells
on AM or AM only. Both groups were given autologous serum
eye drops and immunosuppressive medication. Inclusion and
exclusion criteria are detailed in Supporting Information S1. The
primary endpoint was feasibility and safety and the primary efﬁ-
cacy variable was Best Corrected Visual Acuity. The secondary
efﬁcacy variables were: Ocular Surface Score (OSS—see below)
and Quality of Life (QoL) as assessed by questionnaires VF14,
SF36 [21, 22]. Engraftment of donor cells was assessed by impres-
sion cytology and cytogenetics.
Patients were clinically assessed preoperatively and then
at days 1, 2–3, 7, and 14, and at 1, 3, 6, 9, 12, 15, and
18 months postoperatively with the following investigations
taken: full blood count, liver function tests, urea and electro-
lytes, serum for cytokine analysis, evaluation of corneal vascu-
larization, visual acuity (all time points). DNA ﬁngerprinting of
corneal epithelium (duplicate cultures from manufacturing and
corneal impression samples), using the DNA ﬁngerprinting method
described in references 12, 13, and QoL (VF14 and SF36) assess-
ments were carried out at 6, 12, and 18 months postoperatively.
Treatment Administration and Surgical Technique. The sur-
gical technique was discussed by the ophthalmic surgeons
from the 3 research centers, to develop a consensus describing
the standard operating procedure between investigators. All
surgeons were experienced consultant corneal specialists and
4 consultant surgeons from the 3 centers were involved in this
study. Following a 360 conjunctival peritomy approximately
2–3 mm behind the limbus, a superﬁcial keratectomy was
undertaken to remove abnormal superﬁcial tissue over the
cornea from the underlying corneal stroma. The composite
graft (or control product) was placed upon the exposed cor-
neal stroma with the epithelium facing upward. The graft was
sutured to the limbus, and any remnant material retained for
immunohistochemical analysis (IMP only). A second AM was
placed on top of the ﬁrst graft and sutured peripherally to the
recessed conjunctival edges. A bandage contact lens was then
placed upon the ocular surface to help protect the transplanted
tissue. All patients received perioperative subconjunctival anti-
microbial and steroid injections according to standard of care.
Postoperative Treatment. All patients received postoperative
topical dexamethasone (pf ) 0.1% 2 hourly initially for 2 weeks,
and then gradually tapered (QDS for 1 month, TID for 1 month,
BD for 1 month and then OD thereafter. The steroids were
used for a minimum of 6 months. In addition, patients utilized
autologous serum eye drops for 12 weeks postoperatively. Sys-
temic oral immunosuppression was used as per the protocol
for I year postsurgical treatment: Prednisolone: initial dose of
60 mg daily tapering at 5 mg weekly until 10 mg maintenance
dosage plus Cyclosporine: initial dose of 100 mg twice a day
then tapered to 50 mg twice a day or Mycophenolate mofetil
at a dose between 750 mg and 1 g twice a day.
Table 1. Patient cohort
Patient
number
(from
study) Sex Age
Unilateral
(U) or
bilateral
(B) disease Diagnosis
Product
received
Treatment
site
2 F 50 B Aniridia IMP E
3 M 57 B Pemph IMP G
4b M 48 B Aniridia C E
5a F 49 B CI IMP G
7 M 20 U CI IMP G
8 M 74 B CI C L
9 F 28 B CTD IMP G
10 M 50 B CI C L
11 M 37 B CI C E
12 F 51 B Aniridia IMP G
13 M 51 B Aniridia IMP L
14a F 48 B CI C L
15b M 49 B Aniridia IMP E
16 M 49 B CI C L
17 F 59 B CI IMP L
aDid not complete 18 months follow-up and are excluded from vision
and OSS analysis.
bPatients 4 and 15 are same individual.
Abbreviations: Pemph, ocular cicatricial pemphigoid; CTD, connective
tissue disorder; CI, chemical injury; E, Edinburgh; G, Glasgow; L, Liverpool.
www.StemCellsTM.com © 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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Impression Sampling of Corneal Surface. Impression cytology
to collect samples for DNA analysis was performed using a Milli-
pore ﬁlter paper applicator mounted on a Goldmann tonometer
holder (without prism) held against the corneal surface for
2–3 seconds. Samples were collected at 6, 12, and 18 months
postsurgery.
Safety Assessment. All adverse events (AE) were reported
and recorded in accordance with GCP requirements. Patients
were monitored for any AE during throughout the study. No
AE were attributed to the IMP/control products and no Seri-
ous Adverse Reactions were noted throughout the trial.
Visual Acuity. Visual acuity was measured in the index eye
using a Snellen chart and a LogMAR score allocated as per
Supporting Information Table S1.
OSS. The validated scale described by Shigeru Kinosita’s group
[23] was adopted for the ocular surface scoring system. The
ocular surface was evaluated using a slit lamp giving consider-
ation to a number of parameters: corneal epithelium, conjuncti-
valization, corneal neovascularization, corneal opaciﬁcation and
conjunctival hyperemia each of which was scored on a scale of
0 (“normal”) to 3 (severe damage). A composite score out of
15 was calculated. The key to the scoring system is given in
Supporting Information Table S2.
Measurement of Serum Cytokines. Serum cytokine levels were
measured throughout the trial in order to monitor the overall
immune status of the patients before, during and after the
immune suppression treatment associated with this investiga-
tion. Patient serum samples were collected at regular intervals
and stored at −80C. Samples were assayed for TNF-α, IL-1β,
IL-2, IL-4, IL-6, IL-8/CXCL8), IL-12 and IFN-γ using an eBioscience
ﬂow cytometry cytokine bead array kit (ProcartaPlex Human) and
a MACSQuant 10 instrument (Miltenyi Biotec). Results were gen-
erated against recombinant kit standards and compared against
reported normal ranges for these cytokines detailed in
reference 24.
Statistical Analysis. Patients were grouped according to
whether they had received the IMP or control product. Mean
changes in vision and combined OSS were compared between
the groups at baseline, 6, 12, and 18 months post-treatment.
Statistical analysis was carried out using unpaired t tests, one-
way analysis of variance (ANOVA) and Tukey’s post hoc multiple
comparison test, as appropriate, using Prism 7 software (details
in each section).
RESULTS
Product Manufacture and Quality Control
Deﬁnitive proof that implanted grafts all contained LSC is not
achievable, as any testing would be destructive. Analysis of
remnant material from the 9 transplanted IMPs, showed 5 had
cells positive for p63 and 7 had cells positive for CK3 (repre-
sentative staining Supporting Information Fig. S1). As this is
remnant material from the edge of the implanted graft, this is
not a deﬁnitive proof of LSC content, or lack thereof. Where
p63 positive cells were not detected in remnant material from
the transplanted product, p63+ cells could always be detected
in the duplicate culture, therefore adding weight to the con-
clusion that it is highly likely that all IMP grafts contained LSC.
Patient Recruitment
The study was closed at 32 months, due to slow recruitment. A
total of 30 patients were screened, with 6 deemed not suitable,
7 declined and the remaining 17 enrolled. A total of 16 out of
17 patients, all with total LSCD, were treated in this study. One
patient died of unrelated disease during the trial, and 3 patients
withdrew during the study, therefore 13 patients completed all
assessments as described in the protocol. Mean age of patients
in the IMP (44.3  13) and control (52.1  1.6) groups was not
signiﬁcantly different (p = .246, unpaired t test).
Safety and Adverse Events
A total of 34 AE were recorded in total throughout the dura-
tion of the trial. Raised intraocular pressure was seen in
3 patients (2 from IMP arm and 1 from control). However,
these events could have been related to topical steroid use
postoperatively. Details of all AEs (serious and nonserious) are
described in Supporting Information.
Visual Acuity
The mean visual acuities in the IMP and control arms were not
signiﬁcantly different at the start of the study (Fig. 1) but 5/8
IMP patients ﬁnished the trial with improved visual acuity
scores—a mean improvement in LogMAR score of −0.957 com-
pared with the start of the trial. Two patients received cataract
operations during the trial, which could have improved their
score. The improvement in score from start of trial to end did
not reach statistical signiﬁcance (p = .07) due to the standard
deviation and the small data set (Fig. 1). Scores at 6 and
12 months compared with day 0 were also improved but not
signiﬁcantly different (p = .42 and p = .16, respectively).
In the control arm, 4/5 patients ended the trial with
improved visual acuity scores, mean improvement in LogMAR
score was −0.888. One patient in this group also underwent
Figure 1. Mean  SD visual acuity scores in the investigational
medicinal product (IMP; black bars) and control (gray) groups pre-
treatment and at the 6, 12, and 18 month time points. There is a
trend toward reduction (improvement) in scores throughout the
study, but this does not reach signiﬁcance, and there is no differ-
ence between the IMP or control groups. Two-way analysis of var-
iance, Tukey’s multiple comparisons test. No error bar in “pre”
group for control product as all scores were 3 at start of study.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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cataract surgery. The improvement in score from start of trial to
end did not reach statistical signiﬁcance (p = .22) due to the due
to standard deviation and the small data set (Fig. 1). The mean
improvement in visual acuity at 18 months between treatment
and control arms did not show a signiﬁcant difference (p = .46
unpaired t test).
OSS
The starting mean combined ocular scores in the IMP (10.38)
and control groups (11) were not signiﬁcantly different (p = .65
unpaired t test). In the IMP group, the OSS was signiﬁcantly
improved by the 6 month point and remained signiﬁcantly
improved when compared with the starting score at 12 and
18 months (p = .0043, p = .0018, p = .0002 at 6, 12, and
18 months, respectively (one-way ANOVA Tukey’s Multiple Com-
parisons test; Fig. 2A).
In the control group there was also an initial, signiﬁcant
improvement in scores (p = .014) at 6 months, but the effect
was not sustained, and the improvement in scores returned to
non-signiﬁcance by 12 and 18 months (p = .185 and p = .39,
respectively; all one-way ANOVA, Tukey’s Multiple Compari-
sons test; Fig. 2B).
All patients showed improved OSSs at conclusion of the
trial. Patients who received the IMP showed a signiﬁcantly
higher mean improvement in combined OSSs than those who
received the control (p = .004 unpaired t test) at 18 months
post-transplant (Fig. 2C). Example images of eyes before treat-
ment and at the end of the study, having received control or
IMP are illustrated in Figure 2D.
DNA Analysis
Analysis of donors, and patient corneas prior to administration
of the IMP showed donor and patient DNA in all cases, respec-
tively, as expected. Analysis of cornea lifts from 6/7 evaluable
patients in the IMP arm at 6, 12, and 18 months showed
patient DNA but no evidence of donor DNA. One patient
showed evidence of mixed patient and donor DNA at the
6- and 12-month time points only.
Figure 2. (A): Mean  SD combined ocular surface scores (OSSs) in the investigational medicinal product (IMP) group pretreatment and
at the 6, 12, and 18 month time points. Combined OSS is signiﬁcantly improved (lower) at all time points compared with the beginning
of the trial. **, p ≤ .01; ***, p ≤ .001. One-way analysis of variance (ANOVA), Tukey’s multiple comparisons test. (B): Mean  SD com-
bined OSSs in the control group pretreatment and at the 6, 12, and 18 month time points. Combined OSS is only signiﬁcantly improved
(lower) at 6 months compared with the beginning of the trial and rises to not be signiﬁcantly different from the start scores by
12 months. *, p ≤ .05. One-way ANOVA, Tukey’s multiple comparisons test. (C): Mean  SD change in combined OSSs in the IMP (black)
and control (gray) groups at the end of 18 months follow-up. The mean change in the IMP group is signiﬁcantly improved (lower) com-
pared with the control product group.**, p ≤ .01 unpaired t test. (D): Representative clinical images from the trial. (Di): Preoperative
images from patients before implantation of a control or IMP product. (Dii): Image of IMP product after implantation. (Diii): Eighteen
months post-treatment. Both patients underwent cataract surgery at 7 months (control) and 5 months (IMP) postentry to the study.
Patient who received IMP shows greater corneal clarity and lower levels of neovascluarization. (Div): Image taken 24 months post-LSC
graft—the patient received a corneal transplant at 19 months post-IMP—shows a clear corneal transplant which indicates that the limbal
epithelium has recovered to maintain corneal clarity.
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White Blood Count and Cytokine Levels
White Blood Count (WBC) and cytokine levels were measured
throughout the trial in order to track the effects of immune
suppression, and its withdrawal, as well as measuring underly-
ing indicators of inﬂammatory disease in the patients.
Normal WBC levels were seen in 12/13 enrolled patients
throughout the study. The immunosuppression regimen there-
fore had no gross effect on patient WBC throughout the study
(Supporting Information Fig. S2). One patient with chemical
injury had elevated WBC at presentation and throughout the
clinical study—this patient had ongoing ocular inﬂammation
and had to be withdrawn from the study for subsequent cor-
neal transplant.
Serum Cytokines—At Enrolment. All patients gave samples
for initial cytokine evaluation. An unexpected ﬁnding was that
while 7 patients presented with serum cytokines largely in the
reported normal ranges, 8 patients presented with highly ele-
vated serum levels of multiple cytokines. [24]. Strikingly, all
patients with largely normal cytokine levels (designated “low
cytokine group”) consisted of patients with chemical burns
and the one patient with autoimmune disease (no patients
with aniridia; Fig. 3A). Conversely, 8 patients presented with
at least 3/4 cytokines (TNF-α, IL-1β, IL-2, and IL-8/CXCL8)
higher than the reference ranges and this “high cytokine
group” contained all evaluable patients with aniridia, as well
as 1 with chemical burn, and 1 with an autoimmune disease
(pemphigus; Fig. 3B).
Serum Cytokines—During Clinical Trial
A complete set of serum samples were available to measure
cytokines from 7 patients at completion of the trial—3 from
the low group, and 4 from the high group.
All patients demonstrated normal levels of TNF-α during the
period of immune suppression. In the high cytokine group, ele-
vated levels of TNF-α were detected on withdrawal of immune
suppression at months 15 and 18 (Fig. 3B). This was not associ-
ated with a poor outcome, as all patients with elevated TNF-α
levels had improved visual acuity and OSSs at the end of the trial
(irrespective of receipt of IMP or control product).
In evaluable patients from the high cytokine group, the pre-
operative high levels of IL-8 remained consistently high through-
out the trial with no pattern of suppression toward the normal
range during the period of immune suppression, and after with-
drawal (Fig. 3B). Patients in the low cytokine group did exhibit a
transient increase in serum IL-8 levels at 12 months, but this
quickly returned to the baseline levels thereafter. Again, high
IL-8 levels were not associated with poor outcomes, as all
patients had improved visual acuity and OSSs at the end of the
trial (irrespective of receipt of IMP or control product).
DISCUSSION
This is the ﬁrst randomized controlled study to investigate
safety and efﬁcacy of administering allogeneic deceased-donor
ex vivo expanded corneal epithelial stem cells in severe bilat-
eral OSD arising from LSCD. Our robust study design allowed
Figure 3. (A): Mean serum cytokine levels (SD) in limbal stem cell deﬁciency (LSCD) patients at initial screening for entry to the trial.
Patients can be grouped as having low serum levels of inﬂammatory cytokines at study entry (low group, n = 7) or high levels (high group,
n = 8). All aniridia patients are in the high group. Blue line—representative of maximum reported normal serum levels for each cytokine.
(B): Mean serum cytokine levels (SD) in LSCD patients throughout the trial. Patients initially presenting in the low group (n = 3) show
low levels of TNF-α throughout the period of immune suppression, with a transient increase in mean IL-8 levels on tapering, which
resolves to baseline levels at 18 months. Patients who presented in the high group (n = 4) continue to show very highly elevated levels of
IL-8 throughout the period of immune suppression. TNF-α levels also increase postwithdrawal of immune suppression in this group. Blue
line—representative of maximum reported normal levels for TNF-α and IL-8.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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us to explore the speciﬁc beneﬁts arising from the use of IMP.
In addition, we examined serum cytokine proﬁles in LSCD
patients which have not been previously reported.
IMP
The use of allogeneic deceased-donor limbal tissue introduces
variance due to donor age, time to procurement, transport
conditions, tissue processing and innate biological variability.
We were able to achieve adequate ex vivo outgrowth contain-
ing corneal epithelial stem cells from all but one of the dona-
tions we received. We chose to use AM as a matrix on which
to grow and transfer the cells, rendering this a composite tis-
sue engineered product. QC of such products is not achievable
without sacriﬁcing some product. Therefore, we tested rem-
nant material from the transplanted composite product by
immunohistochemistry. The stem-like p63+ phenotype was
detected in the remnant material from 5 out of the 9 compos-
ite transplanted products. The absence of p63+ cells in 4 may
be because of the limited tissue availability and/or peripheral
nature of the area sampled. Where p63 positive cells were not
detected in remnant material from the transplanted product,
p63+ cells were detected in the duplicate culture, so we may
have a degree of conﬁdence that the transplanted product did
contain LSCD. Kolli et al. [11] describe a gradation in the stem
cell marker p63 in these cultures, with colony formation high-
est proximate to the limbal explants and declining in the more
distal zones of the culture. Expression of CK3 (a marker of dif-
ferentiated corneal epithelium) showed the opposite grada-
tion. In the cultures used for the shelf-life validation, around
half of the products expressed The CK3 marker, whereas in
the transplanted products CK3+ cells were detected in 7 out
of 9 products (and in the duplicate cultures from the 2 clinical
cultures where CK3 was not detected). This indicates our prod-
uct was similar to that manufactured by Kolli et al. Variability
from product to product is likely a function of the original
donated cadaveric material, or the outgrowth region sampled
for immunohistochemistry analysis, as the GMP-compliant
manufacturing process is highly standardized. The IMP shelf-
life of 24 hours at 18C–24C allowed transportation of the
product to clinical centers such as Glasgow and Liverpool
from the manufacturing center (Edinburgh) within the vali-
dated timeframe.
Clinical Trial Outcomes
The IMP was demonstrated to be safe within the limits of the
study, with no serious adverse reactions or events attributed to
the IMP itself. The primary endpoint was improvement in visual
acuity, and there were indicators of transient improvement
throughout the study in both groups. These were not statistically
signiﬁcant, but the majority of patients in both groups ended up
with an improved score at 18 months. The IMP group demon-
strated statistically signiﬁcant and sustained improvement in OSS
over the period of the study. The control group also demon-
strated an initial improvement in OSS, but the effect was not sus-
tained, and the scores returned to near start levels by 18 months.
One patient with aniridia was particularly informative. They
entered the control arm and the OSS improved from 10 to 8 over
18 months. The patient was then readmitted to the study in
respect of his/her other eye and allocated to the IMP arm where
OSS improved from 9 to 3. This patient’s visual acuity also
improved from LogMAR 3 to 2 with control product and from
LogMAR 3 to 1.08 with IMP. It therefore may be asserted with a
degree of conﬁdence that patients receiving the IMP did beneﬁt
overall in terms of OSS improvement, meeting the principal sec-
ondary endpoint of the trial.
The clinical trial was designed as a randomized, controlled
and partially blinded phase I/II trial and hypothesized that the
use of AM, topical autologous serum eye drops and systemic
immunosuppression, may have therapeutic beneﬁt. This clearly
is the case, as both IMP and control groups show initial
improvements in OSS—indeed this is statistically signiﬁcantly
improved in both groups at 6 months. This is not sustained in
the control group, returning to be nonsigniﬁcantly different
from the starting scores, but is clearly sustained in the IMP group.
We may conclude that this study demonstrates a pro-regenerative
role for transplanted LSC in maintaining improved OSS for a signif-
icantly longer time post-transplant than control product. The
mechanism for this role is not associated with long-term donor
cell engraftment, as there is no sign of donor DNA in eyes of the
majority of patients at 6 months. This ﬁnding agrees with 2 ear-
lier studies, one which found no evidence of donor DNA in
7 patients 28 weeks postallografting [13], and one on small
patient numbers (albeit after longer follow-up) who found sus-
tained beneﬁt in eyes receiving LSC, but with no evidence of
engrafted donor DNA [25]. There may be scope to reduce the
period of immune suppression in future trials if this is not
required to support long-term engrafted allogeneic cells.
In this study we were able to compare improvements in
VA between the IMP treatment and control groups, which is a
novel approach in this ﬁeld. In other uncontrolled studies that
included allogeneic donor products (although some were from
related donors) successful improvement of any kind in VA at
the assessment point was seen in, for example, 5/7 patients
[26], 2/7 patients [27], 4/7 patients [28]. We saw overall VA
improvement in 5/8 IMP patients and 4/5 Control patients at
the end of our study. Although generalizations must be drawn
carefully between differing studies and protocols, the results
of our study has at least comparable outcomes in VA changes
to other studies, whether LSC are present or not. The magni-
tude of change is higher with the IMP but not signiﬁcantly so,
this may well be a factor of the small patient numbers and will
require a larger trial to be investigated further.
It should also be noted that randomization led to a skew in
the number of patients with different etiologies completing the
IMP and control groups. Speciﬁcally, 4/8 patients in the IMP group
had aniridia compared with 1/5 in the control group. It is possible
that patients with aniridia respond better to the treatments.
Larger studies with aniridia patients using our IMP are warranted.
The majority of IMP group patients did not display sustained
engraftment of donor DNA suggesting that engraftment is tran-
sient, as described previously [13]. The beneﬁts in OSS for the IMP
group were due to early effects of the stem cells. How these
observations relate to the mode of action is unclear. The IMP
could induce repair of the limbal niche or stimulate small numbers
of dormant residual host stem cells to multiply potentially through
a paracrine or chemotactic mechanism, however this remains
speculative and we believe that more research is required.
Inﬂammation and Underlying Condition
WBC levels were normal in all the evaluable patients except one
throughout the study, with no evidence of suppression-induced
leukopenia and no cytokine bounce-back at withdrawal. Normal
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pretransplant TNF-α levels correlated with the WBC levels indi-
cating no chronic inﬂammation. TNF-α was essentially absent
during immune suppression but did show elevation in a few
patients on tapering of immune suppression which may indicate
responses to cryptic infection, as been reported in other clinical
situations where immune competence is restored after a period
of suppression [29]. IL-8 levels were consistently elevated in anir-
idia patients at pretransplant, but not associated with abnormal
WBC levels or adverse performance after transplantation. IL-8 is
associated with inﬂammation and neovascularization and can be
expressed by various stromal cell types. The nonhematopoetic
origin of IL-8 is indicated via continued high levels in some
patients despite immune suppression. IL-8 levels have been
reported as elevated in tears in aniridia and other eye disorders
[30]. However, it is a normal component of tears, and levels in
eye disorder patients are approximately 2 times reported values
in healthy donors, whereas the levels detected here were
50–500 times normal blood values. This is the ﬁrst report to
the best of our knowledge of chronic, highly elevated serum
IL-8/CXCL8 levels in aniridia.
There was no association with a negative treatment out-
come in patients with high IL-8 levels—all “high cytokine”
patients showed improved VA and OSS at the end of the trial.
However, there may be clinical implications of this ﬁnding sug-
gesting caution in using autologous serum eye drops in aniridia
as the highly elevated levels of proinﬂammatory/proangiogeneic
cytokines may exacerbate aniridia-related OSD. Although the
IMP can improve the ocular surface in aniridia, other ocular
comorbidities associated may limit longer-term beneﬁt.
CONCLUSION AND FUTURE DIRECTIONS
This RCT demonstrates that sustained beneﬁt is achieved by
the IMP in OSD compared with controls and this intervention
warrants further study in larger sample sizes in a phase III
study. New studies would also beneﬁt from concentrating on a
single disease group in order to eliminate some of the vari-
ables in this study. Our ﬁndings in the subgroup with aniridia
suggests that elevated systemic cytokine levels may have clini-
cal relevance and dissecting both ocular and systemic inﬂam-
matory mechanisms in aniridia might shed new light on OSD
pathogenesis associated with this condition.
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